{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:10:13Z","timestamp":1790939413628,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T00:00:00Z","timestamp":1254787200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1038\/nrclinonc.2009.149","type":"journal-article","created":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T08:03:37Z","timestamp":1254816217000},"page":"627-637","source":"Crossref","is-referenced-by-count":107,"title":["Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics"],"prefix":"10.1038","volume":"6","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Skoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Vardiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,6]]},"reference":[{"key":"BFnrclinonc2009149_CR1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek, W. Some speculations on the myeloproliferative syndromes. Blood 6, 372\u2013375 (1951).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman, J. W. et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937\u2013951 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1582-4934.2008.00559.x","volume":"13","author":"A Tefferi","year":"2009","unstructured":"Tefferi, A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J. Cell. Mol. Med. 13, 215\u2013237 (2009).","journal-title":"J. Cell. Mol. Med."},{"key":"BFnrclinonc2009149_CR4","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1038\/leu.2008.231","volume":"22","author":"NC Cross","year":"2008","unstructured":"Cross, N. C. et al. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 22, 1975\u20131989 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR5","doi-asserted-by":"crossref","unstructured":"Skoda, R. The genetic basis of myeloproliferative disorders. Am. Soc. Hematol. Educ Program 1\u201310 (2007).","DOI":"10.1182\/asheducation-2007.1.1"},{"key":"BFnrclinonc2009149_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2009.47","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi, A. et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23, 905\u2013911 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/leu.2009.37","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi, A. et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KIT D816V and FIP1L1-PDGFRA correlates. Leukemia 23, 900\u2013904 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/leu.2009.59","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi, A. et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML. Leukemia 23, 1343\u20131345 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR9","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289\u20132301 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009149_CR10","first-page":"1497","volume":"132","author":"PC Nowell","year":"1960","unstructured":"Nowell, P. C. & Hungerford, D. A. A minute chromosome in human granulocytic leukemia. Science 132, 1497 (1960).","journal-title":"Science"},{"key":"BFnrclinonc2009149_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.leukres.2007.07.007","volume":"32","author":"R Santana-Davila","year":"2008","unstructured":"Santana-Davila, R. et al. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. Leukoc. Res. 32, 407\u2013411 (2008).","journal-title":"Leukoc. Res."},{"key":"BFnrclinonc2009149_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi, A. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110, 1092\u20131097 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","volume":"112","author":"DD Metcalfe","year":"2008","unstructured":"Metcalfe, D. D. Mast cells and mastocytosis. Blood 112, 946\u2013956 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2008.287","volume":"22","author":"J Gotlib","year":"2008","unstructured":"Gotlib, J. & Cools, J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22, 1999\u20132010 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR15","first-page":"18","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"JW Vardiman","year":"2008","unstructured":"Vardiman, J. W. et al. in WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th edn (eds Swerdlow, S. H. et al.) 18\u201330 (WHO, Geneva, 2008)."},{"key":"BFnrclinonc2009149_CR16","first-page":"17","volume-title":"Pathology and Genetics: Tumors of Hematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumors","author":"JW Vardiman","year":"2001","unstructured":"Vardiman, J. W., Brunning, R. D. & Harris, N. L. in Pathology and Genetics: Tumors of Hematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumors (eds Jaffe, E. S. et al.) 17\u201344 (International Agency for Research on Cancer, Lyon, 2001)."},{"key":"BFnrclinonc2009149_CR17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/sj.leu.2405054","volume":"22","author":"E Atallah","year":"2008","unstructured":"Atallah, E. et al. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic\/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia 22, 1295\u20131298 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1053\/j.seminoncol.2005.04.010","volume":"32","author":"J Thiele","year":"2005","unstructured":"Thiele, J. & Kvasnicka, H. M. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin. Oncol. 32, 380\u2013394 (2005).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc2009149_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/10428190500331329","volume":"47","author":"J Thiele","year":"2006","unstructured":"Thiele, J. & Kvasnicka, H. M. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk. Lymphoma 47, 381\u2013396 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2009149_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2141.2007.06568.x","volume":"137","author":"CC So","year":"2007","unstructured":"So, C. C. et al. Can morphological assessment limit the use of specific genetic testing to exclude chronic myeloid leukaemia? Br. J. Hematol. 137, 377 (2007).","journal-title":"Br. J. Hematol."},{"key":"BFnrclinonc2009149_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/ajh.2830270202","volume":"27","author":"DB Stoll","year":"1988","unstructured":"Stoll, D. B. et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am. J. Hematol. 27, 77\u201383 (1988).","journal-title":"Am. J. Hematol."},{"key":"BFnrclinonc2009149_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0344-0338(11)80081-6","volume":"189","author":"T Buhr","year":"1993","unstructured":"Buhr, T., Georgii, A. & Choritz, H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol. Res. Pract. 189, 121\u2013132 (1993).","journal-title":"Pathol. Res. Pract."},{"key":"BFnrclinonc2009149_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1600-0609.2009.01216.x","volume":"82","author":"K Hussein","year":"2009","unstructured":"Hussein, K. et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur. J. Hematol. 82, 255\u2013259 (2009).","journal-title":"Eur. J. Hematol."},{"key":"BFnrclinonc2009149_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1600-0609.2007.01003.x","volume":"80","author":"N Gangat","year":"2008","unstructured":"Gangat, N. et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2 V617F allele burden correlates. Eur. J. Hematol. 80, 197\u2013200 (2008).","journal-title":"Eur. J. Hematol."},{"key":"BFnrclinonc2009149_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","volume":"83","author":"N Gangat","year":"2009","unstructured":"Gangat, N. et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur. J. Hematol. 83, 17\u201321 (2009).","journal-title":"Eur. J. Hematol."},{"key":"BFnrclinonc2009149_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.leu.2403562","volume":"19","author":"MA Elliott","year":"2005","unstructured":"Elliott, M. A. et al. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia 19, 313\u2013317 (2005).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR27","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim, K. H. et al. Systemic mastocytosis in 342 consecutive adults. Blood 113, 5727\u20135736 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","volume":"82","author":"K Hussein","year":"2009","unstructured":"Hussein, K., Van Dyke, D. L. & Tefferi, A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur. J. Hematol. 82, 329\u2013338 (2009).","journal-title":"Eur. J. Hematol."},{"key":"BFnrclinonc2009149_CR29","doi-asserted-by":"crossref","unstructured":"Bacher, U. et al. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS\/MPN category. Ann. Hematol. doi:10.1007\/s00277-009-0745\u20133.","DOI":"10.1007\/s00277-009-0745-3"},{"key":"BFnrclinonc2009149_CR30","first-page":"85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell, P. C. & Hungerford, D. A. Chromosome studies on normal and leukemic human leukocytes. J. Natl Cancer Inst. 25, 85\u2013109 (1960).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2009149_CR31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley, J. D. A new consistent chromosomal abnormalcy in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 243, 290\u2013293 (1973).","journal-title":"Nature"},{"key":"BFnrclinonc2009149_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein, A. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765\u2013767 (1982).","journal-title":"Nature"},{"key":"BFnrclinonc2009149_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen, J. et al. Philadelphia chromosomal breakpoints are clustered within a limited region, BCR, on chromosome 22. Cell 36, 93\u201399 (1984).","journal-title":"Cell"},{"key":"BFnrclinonc2009149_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/315758a0","volume":"315","author":"N Heisterkamp","year":"1985","unstructured":"Heisterkamp, N., Stam, K., Groffen, J., de Klein, A. & Grosveld, G. Structural organization of the BCR gene and its role in the Ph' translocation. Nature 315, 758\u2013761 (1985).","journal-title":"Nature"},{"key":"BFnrclinonc2009149_CR35","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210Bcr\/Abl gene of the Philadelphia chromosome. Science 247, 824\u2013830 (1990).","journal-title":"Science"},{"key":"BFnrclinonc2009149_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561\u2013566 (1996).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2009149_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine, R. L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387\u2013397 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2009149_CR38","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"43","author":"C James","year":"2005","unstructured":"James, C. et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 43, 1144\u20131148 (2005).","journal-title":"Nature"},{"key":"BFnrclinonc2009149_CR39","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779\u20131790 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009149_CR40","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"36","author":"EJ Baxter","year":"2005","unstructured":"Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 36, 1054\u20131061 (2005).","journal-title":"Lancet"},{"key":"BFnrclinonc2009149_CR41","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma, D. P. et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes. Blood 106, 1207\u20131209 (2005).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR42","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones, A. V. et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106, 2162\u20132168 (2005).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR43","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/sj.leu.2404405","volume":"20","author":"A Renneville","year":"2006","unstructured":"Renneville, A. et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 20, 2067\u20132070 (2006).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3324\/haematol.11581","volume":"93","author":"AH Schmitt-Graeff","year":"2008","unstructured":"Schmitt-Graeff, A. H. et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Hematologica 93, 34\u201340 (2008).","journal-title":"Hematologica"},{"key":"BFnrclinonc2009149_CR45","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","volume":"107","author":"G Wernig","year":"2006","unstructured":"Wernig, G. et al. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107, 4274\u20134281 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR46","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","volume":"111","author":"R Tiedt","year":"2008","unstructured":"Tiedt, R. et al. Ratio of mutant Jak2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111, 3931\u20133940 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR47","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","volume":"108","author":"R Kralovics","year":"2006","unstructured":"Kralovics, R. et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108, 1377\u20131380 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR48","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","volume":"25","author":"A Pardanani","year":"2007","unstructured":"Pardanani, A. et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 25, 2358\u20132362 (2007).","journal-title":"Stem Cells"},{"key":"BFnrclinonc2009149_CR49","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","volume":"111","author":"A Pardanani","year":"2008","unstructured":"Pardanani, A., Fridley, B. L., Lasho, T. L., Gilliland, D. G. & Tefferi, A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111, 2785\u20132789 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR50","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones, A. V. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 41, 446\u2013449 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc2009149_CR51","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/ng.342","volume":"41","author":"O Kilpivaara","year":"2009","unstructured":"Kilpivaara, O. et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat. Genet. 41, 455\u2013459 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc2009149_CR52","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ng.341","volume":"41","author":"D Olcaydu","year":"2009","unstructured":"Olcaydu, D. et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet. 41, 450\u2013454 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc2009149_CR53","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott, L. M. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459\u2013468 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009149_CR54","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A. & Tefferi, A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21, 1960\u20131963 (2007).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR55","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","volume":"111","author":"D Pietra","year":"2008","unstructured":"Pietra, D. et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111, 1686\u20131689 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR56","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006).","journal-title":"PLoS Med."},{"key":"BFnrclinonc2009149_CR57","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani, A. D. et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108, 3472\u20133476 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR58","first-page":"2546","volume":"110","author":"S Schnittger","year":"2007","unstructured":"Schnittger, S. et al. Detection of three different MPLW515 mutations in 10.1% of all JAK2 V617 unmutated ET and 9.3% of all JAK2 V617F unmutated OMF: a study of 387 patients. Blood (ASH Annual Meeting Abstracts) 110, 2546 (2007).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFnrclinonc2009149_CR59","first-page":"678","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi, A. M. et al. The clinical phenotype of patients with essential thrombocythemia harboring MPL 515W>L\/K mutation. Blood (ASH Annual Meeting Abstracts) 110, 678 (2007).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFnrclinonc2009149_CR60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","volume":"137","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli, P. et al. Anemia characterises patients with myelofibrosis harboring MPL mutation. Br. J. Haematol. 137, 244\u2013247 (2007).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2009149_CR61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer, P. A. et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112, 141\u2013149 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR62","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","volume":"110","author":"R Chalign\u00e9","year":"2007","unstructured":"Chalign\u00e9, R. et al. Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 110, 3735\u20133743 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR63","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/sj.leu.2404749","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani, A., Lasho, T. L., Finke, C., Markovic, S. N. & Tefferi, A. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia 21, 2206\u20132207 (2007).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR64","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","volume":"135","author":"TL Lasho","year":"2006","unstructured":"Lasho, T. L. et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br. J. Haematol. 135, 683\u2013687 (2006).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2009149_CR65","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1365-2141.2008.07560.x","volume":"144","author":"PA Beer","year":"2009","unstructured":"Beer, P. A. et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br. J. Haematol. 144, 904\u2013908 (2009).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2009149_CR66","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1172\/JCI116761","volume":"92","author":"T Furitsu","year":"1993","unstructured":"Furitsu, T. et al. Identification of mutations in the coding sequence of the proto-oncogene c-KIT in a human mast cell leukemia cell line causing ligand-independent activation of c-KIT product. J. Clin. Invest. 92, 1736\u20131744 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc2009149_CR67","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero, A. C. et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108, 2366\u20132372 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR68","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20050807","volume":"202","author":"JP Zappulla","year":"2005","unstructured":"Zappulla, J. P. et al. Mastocytosis in mice expressing human KIT receptor with the activating Asp816Val mutation. J. Exp. Med. 202, 1635\u20131641 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrclinonc2009149_CR69","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0145-2126(02)00272-2","volume":"27","author":"PT Ferrao","year":"2003","unstructured":"Ferrao, P. T., Gonda, T. J. & Ashman, L. K. Constitutively active mutant D816VKit induces megakaryocyte and mast cell differentiation of early hemopoietic cells from murine fetal liver. Leukoc. Res. 27, 547\u2013555 (2003).","journal-title":"Leukoc. Res."},{"key":"BFnrclinonc2009149_CR70","first-page":"3","volume":"112","author":"F Delhommeau","year":"2008","unstructured":"Delhommeau, F. et al. TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a pre-JAK2 V617F event. Blood (ASH Annual Meeting Abstracts) 112, 3 (2008).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFnrclinonc2009149_CR71","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/leu.2009.54","volume":"23","author":"MM Patnaik","year":"2009","unstructured":"Patnaik, M. M. & Tefferi, A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia 23, 834\u2013844 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1365-2141.2002.03386.x","volume":"117","author":"M Messinezy","year":"2002","unstructured":"Messinezy, M. et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br. J. Haematol. 117, 47\u201353 (2002).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2009149_CR73","first-page":"1194","volume":"89","author":"P Mossuz","year":"2004","unstructured":"Mossuz, P. et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Hematologica 89, 1194\u20131198 (2004).","journal-title":"Hematologica"},{"key":"BFnrclinonc2009149_CR74","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi, A. & Vardiman, J. W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22, 14\u201322 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009149_CR75","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/cncr.22663","volume":"109","author":"J Kittur","year":"2007","unstructured":"Kittur, J. et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109, 2279\u20132284 (2007).","journal-title":"Cancer"},{"key":"BFnrclinonc2009149_CR76","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood.V90.7.2768","volume":"90","author":"D Blickstein","year":"1997","unstructured":"Blickstein, D. et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation. Blood 90, 2768\u20132771 (1997).","journal-title":"Blood"},{"key":"BFnrclinonc2009149_CR77","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","volume":"133","author":"A Tefferi","year":"2006","unstructured":"Tefferi, A., Patnaik, M. M. & Pardanani, A. Eosinophilia: secondary, clonal and idiopathic. Br. J. Haematol. 133, 468\u2013492 (2006).","journal-title":"Br. J. Haematol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.149","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:02:29Z","timestamp":1684468949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,6]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["BFnrclinonc2009149"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.149","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,6]]}}}